HUTCHMED (NASDAQ:HCM) Shares Gap Down to $18.46

Shares of HUTCHMED (China) Limited (NASDAQ:HCMGet Free Report) gapped down prior to trading on Monday . The stock had previously closed at $18.46, but opened at $17.40. HUTCHMED shares last traded at $17.15, with a volume of 14,298 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Monday, June 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.70.

Get Our Latest Stock Report on HUTCHMED

HUTCHMED Trading Up 0.9 %

The company has a quick ratio of 2.60, a current ratio of 2.72 and a debt-to-equity ratio of 0.06. The firm’s fifty day moving average is $18.74 and its 200 day moving average is $16.90.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of HUTCHMED by 353.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock worth $65,000 after purchasing an additional 2,801 shares during the period. Baillie Gifford & Co. increased its holdings in shares of HUTCHMED by 7.2% during the 4th quarter. Baillie Gifford & Co. now owns 144,969 shares of the company’s stock worth $2,625,000 after purchasing an additional 9,694 shares during the period. Hsbc Holdings PLC increased its holdings in shares of HUTCHMED by 821.2% during the 4th quarter. Hsbc Holdings PLC now owns 206,544 shares of the company’s stock worth $3,720,000 after purchasing an additional 184,123 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of HUTCHMED by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock worth $958,000 after purchasing an additional 1,388 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of HUTCHMED by 54.9% during the 1st quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company’s stock worth $721,000 after purchasing an additional 15,221 shares during the period. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

(Get Free Report)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.

Further Reading

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.